Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance

Mesoblast LimitedTrade
Vanguard Emerging Markets Stock Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Mesoblast Limited trades at $16.86 (market cap $2.21B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.42. The key difference: Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

MESOVWO
Market Cap
$2.21B
Sector
Technology
52-Week High
$20.96$61.24
52-Week Low
$12.88$51.20
Enterprise Value
$2.21B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.

Vanguard Emerging Markets Stock Index Fund ETF

VWO trades at $60.42, up 0.15% today, with a bullish technical signal driven by moving averages. The ETF shows strong institutional accumulation, with Barry Investment Advisors increasing holdings by 6.1% (SEC filing, August 10, 2026). RSI levels indicate mild overbought conditions, while support sits near $60.

Outlook remains positive due to record capital inflows into emerging markets and low 0.06% expense ratio. Risks include concentrated exposure to developing economies and China's economic volatility. The dividend yield of 2.4% offers income appeal amid global diversification trends.

Returns comparison

Trailing returns across standard periods

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO

About Vanguard Emerging Markets Stock Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.

Read more on VWO